Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial.
Authors
Pavel, MHörsch, D
Caplin, M
Ramage, J
Seufferlein, T
Valle, Juan W
Banks, P
Lapuerta, P
Sands, A
Zambrowicz, B
Fleming, D
Wiedenmann, B
Affiliation
Charité - Universitätsmedizin , Department of Gastroenterology and Hepatology, 13353 Berlin GermanyIssue Date
2015-04
Metadata
Show full item recordAbstract
Carcinoid syndrome (CS) is associated with elevated serotonin, diarrhea, flushing, and increased risk of valvular heart disease. Many patients respond to somatostatin analogs initially, but response diminishes in most patients. Additional options are needed.Citation
Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. 2015, 100 (4):1511-9 J Clin Endocrinol MetabJournal
The Journal of Clinical Endocrinology and MetabolismDOI
10.1210/jc.2014-2247PubMed ID
25636046Type
ArticleLanguage
enISSN
1945-7197ae974a485f413a2113503eed53cd6c53
10.1210/jc.2014-2247
Scopus Count
Collections
Related articles
- Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
- Authors: Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, Kunz PL, Hörsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, Garcia-Carbonero R
- Issue date: 2018 Mar
- Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
- Authors: Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A
- Issue date: 2014 Oct
- TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.
- Authors: Strosberg J, Joish VN, Giacalone S, Perez-Olle R, Fish-Steagall A, Kapoor K, Dharba S, Lapuerta P, Benson AB
- Issue date: 2019 Nov
- Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
- Authors: Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M
- Issue date: 2017 Jan
- Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.
- Authors: Masab M, Saif MW
- Issue date: 2017 Dec